Developer docs
API playgroundTry for free, no card

Search company profiles

OncXerna Therapeutics

Full company profile

uuid0000fmk

Namestring
OncXerna Therapeutics
Legal namestring
OncXerna Therapeutics, Ltd.
Websiteurl
oncxerna.com
Company typeenum
Private
Founded yearint
2018
Short descriptiontext

OncXerna Therapeutics is a clinical-stage precision oncology biotech developing RNA-based biomarker-guided bispecific antibody therapies for cancer patients, headquartered in Waltham, Massachusetts and incorporated in the Cayman Islands.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersWaltham, United States
HQ citystring
Waltham
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
bispecific antibodies, oncology therapeutics, precision medicine, RNA biomarker platform, cancer immunotherapy
Industry3 codes
1Oncology & Hematology Pharmaceuticals
CodeHLAIAAACPrimaryYes
2Oncology Specialty Pharmaceuticals
CodeHLAIACAAPrimaryNo
3Companion Diagnostics (CDx) Development & Commercialization
CodeHLAAANACPrimaryNo
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical and Medicine Manufacturing3254
Product category
Oncology Biopharmaceuticals
Social media profiles1 record
Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

OncXerna Therapeutics is a clinical-stage biopharmaceutical company developing bispecific antibody therapies for cancer treatment. The company's pipeline is enabled by its proprietary RNA-based biomarker platform that informs precision medicine approaches for oncology patients. The firm operates as a privately held, for-profit pharmaceutical entity headquartered in Waltham, Massachusetts.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Bispecific Antibody Therapeutics Pipeline
CategoryOncology Biopharmaceuticals
Scale indicator1 record

Each record includes

Type, Value, Description, Source

Market position
Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

OncXerna Therapeutics

Oncology Biopharmaceuticalsoncxerna.com

OncXerna Therapeutics is a clinical-stage precision oncology biotech developing RNA-based biomarker-guided bispecific antibody therapies for cancer patients, headquartered in Waltham, Massachusetts and incorporated in the Cayman Islands.

OncXerna Therapeutics firmographics

Firmographics
Name
OncXerna Therapeutics
Legal name
OncXerna Therapeutics, Ltd.
Website
https://oncxerna.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Short description
OncXerna Therapeutics is a clinical-stage precision oncology biotech developing RNA-based biomarker-guided bispecific antibody therapies for cancer patients, headquartered in Waltham, Massachusetts and incorporated in the Cayman Islands.
Ownership category
akta.pro rank

OncXerna Therapeutics industry classification

Industry
Product category
Oncology Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)
akta.pro primary industry
Oncology & Hematology Pharmaceuticals (HLAIAAAC)
akta.pro secondary industries
Oncology Specialty Pharmaceuticals (HLAIACAA), Companion Diagnostics (CDx) Development & Commercialization (HLAAANAC)

Keywords

  • Bispecific antibodies
  • Oncology therapeutics
  • Precision medicine
  • RNA biomarker platform
  • Cancer immunotherapy

Where OncXerna Therapeutics is headquartered

Location

Headquarters

HQ city
Waltham
HQ country
United States
HQ region
North America

Offices1 record

Markets served

OncXerna Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

OncXerna Therapeutics product offering

Product offering

Core offering

OncXerna Therapeutics is a clinical-stage biopharmaceutical company developing bispecific antibody therapies for cancer treatment. The company's pipeline is enabled by its proprietary RNA-based biomarker platform that informs precision medicine approaches for oncology patients. The firm operates as a privately held, for-profit pharmaceutical entity headquartered in Waltham, Massachusetts.

Differentiator

Problem solved

Functional benefit

Products and services

  • Bispecific Antibody Therapeutics Pipeline

Companies that use OncXerna Therapeutics

Customer profile

Segments1 record

Ideal customer profiles1 record

OncXerna Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

OncXerna Therapeutics partnerships and signals

Strategic signal

Scale indicators1 record

OncXerna Therapeutics competitors and assessment

Company assessment

Market position

Customer concentration

OncXerna Therapeutics social profiles

Digital presence

OncXerna Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

OncXerna Therapeutics leadership team

Management profile

Number of profiles

Profiles4 records

OncXerna Therapeutics funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

OncXerna Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about OncXerna Therapeutics

What does OncXerna Therapeutics do?

OncXerna Therapeutics is a clinical-stage biopharmaceutical company developing bispecific antibody therapies for cancer treatment. The company's pipeline is enabled by its proprietary RNA-based biomarker platform that informs precision medicine approaches for oncology patients. The firm operates as a privately held, for-profit pharmaceutical entity headquartered in Waltham, Massachusetts.

Is OncXerna Therapeutics a public or private company?

OncXerna Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was OncXerna Therapeutics founded?

OncXerna Therapeutics was founded in 2018. It employs 11 to 50 people.

Where is OncXerna Therapeutics based?

OncXerna Therapeutics is headquartered in Waltham, United States, in the North America region.

Does OncXerna Therapeutics have an API?

No public API is recorded for OncXerna Therapeutics.

What industry is OncXerna Therapeutics in?

OncXerna Therapeutics's product category is Oncology Biopharmaceuticals. Its primary akta.pro industry code is HLAIAAAC, Oncology & Hematology Pharmaceuticals, with a secondary code of HLAIACAA, Oncology Specialty Pharmaceuticals. Its NAICS code is 325414.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireBispecific Antibodies Market Report 2025- 2035, with Profiles of Akeso Biopharma, Alexion, Amgen, Genmab, Immunocore, Linton Pharm, Merck, OncXerna Therapeutics, Zymeworks, and MoreThe global bispecific antibodies market is projected to grow from USD 5.6 billion in 2025 to USD 16.8 billion by 2035, a CAGR of 9.5%. Growth is driven by advancements in monoclonal antibodies and strategic partnerships, with North America leading and hematological malignancies emerging rapidly.GlobeNewswireOncXerna Therapeutics Announces Upcoming ASCO Poster Featuring Data Showing the Phase 2 Glioblastoma Trial of Bavituximab with Chemoradiation and Adjuvant Temozolomide Met its Primary EndpointOncXerna announced Phase 2 trial data for bavituximab with chemoradiation and temozolomide in glioblastoma, meeting the primary endpoint of 72% 12-month overall survival. The trial reported 73% OS-12, median overall survival of 15.4 months, and a 91% disease control rate. The company plans to explore combining bavituximab with checkpoint inhibitors.GlobeNewswireOncXerna Therapeutics Highlights the Xerna™ TME Panel’s Prognostic and Predictive Value Across Indications and Therapeutic Classes at the AACR Annual MeetingOncXerna Therapeutics presented data at the AACR Annual Meeting showing its Xerna TME Panel's prognostic value across multiple tumor types. The panel predicted clinical benefit in gastric cancer patients treated with ramucirumab and showed better predictive value than PD-L1 and MSI-H in immune checkpoint inhibitor monotherapy. The panel is licensed to Qiagen and Exact Sciences for clinical trials.GlobeNewswireOncXerna Therapeutics Appoints C. Evan Ballantyne as Chief Financial OfficerOncXerna Therapeutics appointed Evan Ballantyne as Chief Financial Officer. Ballantyne brings over 27 years of executive experience, including CFO roles at Orchestra Biomed, Cerecin, and Agenus. He will support advancing the company's pipeline and Xerna platform.GlobeNewswireOncXerna Therapeutics to Present at The LifeSci Partners Private Company Summer SymposiumOncXerna Therapeutics announced that CEO Laura Benjamin will present at the LifeSci Partners Private Company Summer Symposium on July 22, 2021. The company's Xerna platform uses RNA-based biomarkers to identify patients for its targeted therapies, including navicixizumab and bavituximab, which are investigational.GlobeNewswireOncologie Announces New Data and Analyses from Clinical Programs and Name Change to OncXerna TherapeuticsOncXerna Therapeutics announced interim results from its bavituximab and navicixizumab trials, showing a 19% overall response rate in gastric cancer and a 70% response in biomarker-positive ovarian cancer patients. The company also renamed itself OncXerna Therapeutics, citing its RNA-based biomarker platform's ability to predict treatment response.